However, the modest improvements seen with SGLT2-inhibitor therapy in these domains do not provide a clear explanation for the striking benefits observed in heart failure events in the large clinical trials and key pathways involved still require further investigation. This evidence concerns the gene SLC5A2 and heart failure.